25 results
Thumbnail

D3.230 - Type I Hypersensitivity Among Private Dental Practitioners: Clinical Manifestations and Associated Factors

Thumbnail

D3.221 - Cat Immunotherapy and Real-Life Data: A Single-Center Experience

Thumbnail

D3.220 - Real-World Management of Pediatric Allergic Diseases: A Nationwide Physician Survey among Allergists and Pediatric Allergists in Turkey

Thumbnail

D3.215 - Shifting patterns of mite sensitization in Southern Europe: Real-World diagnostic and immunotherapy practices in Spain and Portugal (MITE-WISE Project)

Thumbnail

D3.216 - Determination of Allergenic Activity of Native Mugwort Allergen Preparations by a Competitive IgE-Binding Test

Thumbnail

D3.217 - Development and validation of a monoclonal antibody-based competitive ELISA to accurate quantification of Blo t 2 in native Blomia tropicalis allergenic extracts

Thumbnail

D3.218 - When the sting is not the sensitizer: a vespid venom allergy case

Thumbnail

D3.222 - Monitoring the immune response during the first year of SCIT in Ragweed allergy

Thumbnail

D3.223 - Crossroads of Venom and Bite: A case of Horsefly - Wasp Cross - reactive Anaphylaxis

Thumbnail

D3.225 - Two years Sublingual SQ-Grass Pollen Tablet Immunotherapy Combined with Dupilumab Induces Longterm Suppression of Immediate Cutaneous Allergen Sensitivity

Thumbnail

D3.226 - Prophylactic sublingual peanut immunotherapy alters antibody responses and downstream allergen reactivity in a Brown Norway rat model

Thumbnail

D3.227 - The effect of subcutaneous allergen immunotherapy after one year on the quality of life of children with perennial allergic rhinitis and rhinoconjunctivitis

Thumbnail

D3.228 - One-Year Changes in Molecular sIgE Profiles During House Dust Mite Immunotherapy: A Pilot Study

Thumbnail

D3.229 - Comparison of mold sensitization profiles in children (2021 and 2025): impact of environmental deterioration during martial law

Thumbnail

D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)

Thumbnail

D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety

Thumbnail

D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A

Thumbnail

D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody

Thumbnail

D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series

Thumbnail

D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria